Pharmaron Beijing Co., Ltd. (SHE:300759)
China flag China · Delayed Price · Currency is CNY
47.98
-2.92 (-5.74%)
Aug 21, 2026, 3:04 PM CST

Pharmaron Beijing Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
1,5761,0171,6905,9191,4973,544
Short-Term Investments
-885.65257.27179.36613.241,080
Trading Asset Securities
876.2714.071,115594.33745.361,555
Cash & Short-Term Investments
2,4522,6173,0626,6932,8566,178
Cash Growth
-13.56%-14.54%-54.24%134.33%-53.77%60.37%
Accounts Receivable
3,3893,1882,8712,6362,2141,424
Other Receivables
79.3758.2126.8980.9871.1692.43
Receivables
3,8393,2462,9982,7172,2861,516
Inventory
1,9351,4721,1171,0131,041680.04
Other Current Assets
643.79442.71430.73451.33352.82269.05
Total Current Assets
8,8707,7787,60810,8746,5368,644
Property, Plant & Equipment
12,53611,97010,79810,0628,4645,811
Long-Term Investments
1,4881,158883.041,0051,008762.67
Goodwill
3,5083,5862,7612,7812,6882,096
Other Intangible Assets
1,2581,197791789.06802.53692.94
Long-Term Deferred Tax Assets
268.76262.91192.68153.2258.7915.6
Long-Term Deferred Charges
583.91617.99678.5520.47496.38171.6
Other Long-Term Assets
380.13465.28155.44267.09438.91195.99
Total Assets
28,94627,09423,92726,47720,49318,389

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
761.26606.59477.09412.22406.35315.53
Accrued Expenses
966.611,050853.93805.65784.92626.21
Short-Term Debt
1,1391,265764.97577.07662.77421.76
Current Portion of Long-Term Debt
3,4153,501282.34150.3474.9460.54
Current Portion of Leases
126.68122.7149.51185.32164.0395.29
Current Income Taxes Payable
79.83133.2160.08184.55145.8781.34
Current Unearned Revenue
1,168960.61834.86740.87832.14679.62
Other Current Liabilities
1,066724.9701.23598.47841.4701.7
Total Current Liabilities
8,7228,3644,2243,6543,9122,982
Long-Term Debt
1,9201,7724,3778,2004,4544,423
Long-Term Leases
352.71379.42401.31585.2760.51284.34
Long-Term Unearned Revenue
446.17442.86409.98391.71152.38149.44
Long-Term Deferred Tax Liabilities
453.66397.15291.87290.04261.01173.3
Other Long-Term Liabilities
---117.58112.0981.56
Total Liabilities
11,89611,3559,70513,2399,6538,094

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
1,8371,7791,7781,7871,191794.18
Additional Paid-In Capital
5,8924,9505,0085,2225,2546,008
Retained Earnings
8,9538,5687,2575,8184,5743,554
Treasury Stock
-227.55-304.89-416.27-463.45-668.04-301.83
Comprehensive Income & Other
-106.7271.8-7.76193.72197.2674.15
Total Common Equity
16,34915,06413,61912,55710,54910,129
Minority Interest
702.02674.38603.54681.25291.25166.07
Shareholders' Equity
17,05115,73914,22313,23810,84010,295
Total Liabilities & Equity
28,94627,09423,92726,47720,49318,389

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
6,9547,0405,9759,6986,1175,285
Net Cash (Debt)
-4,501-4,423-2,913-3,005-3,260893.04
Net Cash Growth
------68.12%
Net Cash Per Share
-2.50-2.50-1.64-1.69-1.840.49
Filing Date Shares Outstanding
1,8301,8301,7661,7871,7871,787
Total Common Shares Outstanding
1,8301,7711,7661,7871,7871,787
Working Capital
147.4-585.843,3847,2202,6245,662
Book Value Per Share
8.938.517.717.035.905.67
Tangible Book Value
11,58310,28210,0688,9877,0587,340
Tangible Book Value Per Share
6.335.815.705.033.954.11
Buildings
6,1495,6474,9213,9713,3472,473
Machinery
8,0627,5956,2745,1494,2652,919
Construction In Progress
2,4692,3652,2542,6331,6711,374